These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9278949)

  • 21. Apomorphine effects on episodic memory in young healthy volunteers.
    Montoya A; Lal S; Menear M; Duplessis E; Thavundayil J; Schmitz N; Lepage M
    Neuropsychologia; 2008 Jan; 46(1):292-300. PubMed ID: 17765272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth hormone response to apomorphine in obsessive-compulsive disorder.
    Pitchot W; Hansenne M; Moreno AG; Ansseau M
    J Psychiatry Neurosci; 1996 Nov; 21(5):343-5. PubMed ID: 8973055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of dieting and weight loss on neuroendocrine responses to tryptophan, clonidine, and apomorphine in volunteers. Important implications for neuroendocrine investigations in depression.
    Goodwin GM; Fairburn CG; Cowen PJ
    Arch Gen Psychiatry; 1987 Nov; 44(11):952-7. PubMed ID: 3675135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroendocrine profile of SDZ HDC-912 and OPC-4392, two new atypical antipsychotic drugs, in schizophrenic patients.
    Duval F; Mokrani MC; Macher JP; Crocq MA; Castro JO; Bailey P; Lataste X
    Psychopharmacology (Berl); 1993; 110(1-2):177-80. PubMed ID: 7870880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroendocrine evidence for increased responsiveness of dopamine receptors in humans following electroconvulsive therapy.
    Balldin J; Granérus AK; Lindstedt G; Modigh K; Wålinder J
    Psychopharmacology (Berl); 1982; 76(4):371-6. PubMed ID: 6812112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of short-term administration of valproate on serotonin-1A and dopamine receptor function in healthy human subjects.
    Delva NJ; Brooks DL; Franklin M; al-Said K; Hawken ER; Merali Z; Lawson JS; Ravindran AV
    J Psychiatry Neurosci; 2002 Nov; 27(6):429-37. PubMed ID: 12491576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
    Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
    Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of ECT on the neuroendocrine response to apomorphine in severely depressed patients.
    Christie JE; Whalley LJ; Brown NS; Dick H
    Br J Psychiatry; 1982 Mar; 140():268-73. PubMed ID: 6807386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of carbamazepine on dopamine- and serotonin-mediated neuroendocrine responses.
    Elphick M; Yang JD; Cowen PJ
    Arch Gen Psychiatry; 1990 Feb; 47(2):135-40. PubMed ID: 2105705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CCK-8 antagonizes apomorphine-induced growth hormone secretion in normal subjects.
    Nair NP; Lal S; Eugenio H; Lizondo E; Thavundayil JX; Wood PL; Etienne P; Guyda H
    Horm Metab Res; 1986 Jan; 18(1):53-5. PubMed ID: 3949282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apomorphine inhibits the growth-stimulating effect of retinal pigment epithelium on scleral cells in vitro.
    Seko Y; Tanaka Y; Tokoro T
    Cell Biochem Funct; 1997 Sep; 15(3):191-6. PubMed ID: 9377797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine.
    Depoortere R; Perrault G; Sanger DJ
    Psychopharmacology (Berl); 1996 Apr; 124(3):231-40. PubMed ID: 8740044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of methyltestosterone on the growth hormone response to the dopamine receptor agonist, apomorphine.
    Lal S; Nair NP; Thavundayil JX; Tawar V; Guyda H; Ayotte C
    Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(2):263-8. PubMed ID: 1871327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychopathological correlates of dopaminergic disturbances in major depression.
    Pitchot W; Hansenne M; Moreno AG; von Frenckell R; Ansseau M
    Neuropsychobiology; 1990-1991; 24(4):169-72. PubMed ID: 2135707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Light modulates dopamine-regulated Walsh inhibitor activity and dopamine-dependent cyclic AMP accumulation in the rabbit retina.
    Nowak JZ; Zawilska J; Sek B; Schorderet M
    Pol J Pharmacol Pharm; 1990; 42(5):457-70. PubMed ID: 1983030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopamine agonists at repeated "autoreceptor-selective" doses: effects upon the sensitivity of A10 dopamine autoreceptors.
    Jeziorski M; White FJ
    Synapse; 1989; 4(4):267-80. PubMed ID: 2603146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drugs and the frog retina. Effect of dopaminergic agents on the pigment screening of light- and dark-adapted frogs.
    Kemali M; Milici N; Kemali D
    Neuropharmacology; 1984 Mar; 23(3):381-5. PubMed ID: 6610134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of dopamine agonists in tardive dyskinesia.
    Smith RC; Tamminga CA; Haraszti J; Pandey GN; Davis JM
    Am J Psychiatry; 1977 Jul; 134(7):763-8. PubMed ID: 869053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of sulpiride, an atypical neuroleptic, on apomorphine-induced growth hormone secretion.
    Nair NP; Lal S; Iskandar HI; Etienne P; Wood PL; Guyda H
    Brain Res Bull; 1982 Jun; 8(6):587-91. PubMed ID: 7139355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Noradrenergic and dopaminergic interrelation in schizophrenia.
    Brambilla F; Marini S; Saito A; Fassone G; Picardi A; Nerozzi D; Pancheri P
    Psychiatry Res; 1994 Sep; 53(3):231-42. PubMed ID: 7870845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.